Guardant Health Guardant Reveal

Guardant Health has launched Guardant Reveal, a blood-based liquid biopsy test for the detection of residual and recurrent disease in cancer patients. Intended initially for the early-stage colorectal cancer space, the assay detects circulating tumor DNA in patients' blood to identify those with residual disease who may benefit most from adjuvant therapy and/or detect the first signs of a recurrence. Results are returned in as little as seven days without the need for a tissue biopsy.